ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib von Li, Yiting, Zang, Hongjing, Qian, Guoqing, Owonikoko, Taofeek K., Ramalingam, Suresh R., Sun, Shi‐Yong

Volltext

The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib-resistant EGFR-mutant NSCLC cell... von Liu, Chaoyuan, Qian, Luxi, Vallega, Karin A, Ma, Guangzhi, Zong, Dan, Chen, Luxiao, Wang, Shaomeng, Ramalingam, Suresh R, Qin, Zhaohui, Sun, Shi-Yong

Volltext

MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor–mutant lung cancers von Gu, Jiajia, Yao, Weilong, Shi, Puyu, Zhang, Guojing, Owonikoko, Taofeek K., Ramalingam, Suresh S., Sun, Shi‐Yong

Volltext

ERK inhibition effectively overcomes acquired resistance of EGFR-mutant NSCLC cells to osimertinib von Li, Yiting, Zang, Hongjing, Qian, Guoqing, Owonikoko, Taofeek K., Ramalingam, Suresh R., Sun, Shi-Yong

Volltext

Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature von Pillai, Rathi N., Behera, Madhusmita, Owonikoko, Taofeek K., Kamphorst, Alice O., Pakkala, Suchita, Belani, Chandra P., Khuri, Fadlo R., Ahmed, Rafi, Ramalingam, Suresh S.

Volltext

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer von Mok, Tony S, Wu, Yi-Long, Ahn, Myung-Ju, Garassino, Marina C, Kim, Hye R, Ramalingam, Suresh S, Shepherd, Frances A, He, Yong, Akamatsu, Hiroaki, Theelen, Willemijn S.M.E, Lee, Chee K, Sebastian, Martin, Templeton, Alison, Mann, Helen, Marotti, Marcelo, Ghiorghiu, Serban, Papadimitrakopoulou, Vassiliki A

Volltext

Lung cancer: New biological insights and recent therapeutic advances von Ramalingam, Suresh S., Owonikoko, Taofeek K., Khuri, Fadlo R.

Volltext

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers von Ready, Neal, Hellmann, Matthew D, Awad, Mark M, Otterson, Gregory A, Gutierrez, Martin, Gainor, Justin F, Borghaei, Hossein, Jolivet, Jacques, Horn, Leora, Mates, Mihaela, Brahmer, Julie, Rabinowitz, Ian, Reddy, Pavan S, Chesney, Jason, Orcutt, James, Spigel, David R, Reck, Martin, O'Byrne, Kenneth John, Paz-Ares, Luis, Hu, Wenhua, Zerba, Kim, Li, Xuemei, Lestini, Brian, Geese, William J, Szustakowski, Joseph D, Green, George, Chang, Han, Ramalingam, Suresh S

Volltext

Sotorasib for Lung Cancers with KRAS p.G12C Mutation von Skoulidis, Ferdinandos, Li, Bob T, Dy, Grace K, Price, Timothy J, Falchook, Gerald S, Wolf, Jürgen, Italiano, Antoine, Schuler, Martin, Borghaei, Hossein, Barlesi, Fabrice, Kato, Terufumi, Curioni-Fontecedro, Alessandra, Sacher, Adrian, Spira, Alexander, Ramalingam, Suresh S, Takahashi, Toshiaki, Besse, Benjamin, Anderson, Abraham, Ang, Agnes, Tran, Qui, Mather, Omar, Henary, Haby, Ngarmchamnanrith, Gataree, Friberg, Gregory, Velcheti, Vamsidhar, Govindan, Ramaswamy

Volltext

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium von Pillai, Rathi N., Behera, Madhusmita, Berry, Lynne D., Rossi, Mike R., Kris, Mark G., Johnson, Bruce E., Bunn, Paul A., Ramalingam, Suresh S., Khuri, Fadlo R.

Volltext

The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer von Smeltzer, Matthew P., Wynes, Murry W., Lantuejoul, Sylvie, Soo, Ross, Ramalingam, Suresh S., Varella-Garcia, Marileila, Meadows Taylor, Meghan, Richeimer, Kristin, Wood, Kelsey, Howell, Kristen E., Dalurzo, Mercedes Lilana, Felip, Enriqueta, Hollenbeck, Gina, Kerr, Keith, Kim, Edward S., Mathias, Clarissa, Pacheco, Jose, Postmus, Pieter, Powell, Charles, Tsuboi, Masahiro, Wistuba, Ignacio I., Wakelee, Heather A., Belani, Chandra P., Scagliotti, Giorgio V., Hirsch, Fred R.

Volltext

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer von Gerber, David E., Camidge, D. Ross, Morgensztern, Daniel, Cetnar, Jeremey, Kelly, Ronan J., Ramalingam, Suresh S., Spigel, David R., Jeong, Woondong, Scaglioni, Pier P., Zhang, Song, Li, Marilyn, Weaver, David T., Vaikus, Louis, Keegan, Mitchell, Horobin, Joanna C., Burns, Timothy F.

Volltext

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, s... von Rizvi, Naiyer A, Dr, Mazières, Julien, Prof, Planchard, David, MD, Stinchcombe, Thomas E, MD, Dy, Grace K, MD, Antonia, Scott J, MD, Horn, Leora, MD, Lena, Hervé, MD, Minenza, Elisa, MD, Mennecier, Bertrand, MD, Otterson, Gregory A, MD, Campos, Luis T, MD, Gandara, David R, MD, Levy, Benjamin P, MD, Nair, Suresh G, MD, Zalcman, Gérard, Prof, Wolf, Jürgen, Prof, Souquet, Pierre-Jean, MD, Baldini, Editta, MD, Cappuzzo, Federico, MD, Chouaid, Christos, MD, Dowlati, Afshin, MD, Sanborn, Rachel, MD, Lopez-Chavez, Ariel, MD, Grohe, Christian, Prof, Huber, Rudolf M, Prof, Harbison, Christopher T, PhD, Baudelet, Christine, PhD, Lestini, Brian J, MD, Ramalingam, Suresh S, Prof

Volltext

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial von de Langen, Adrianus Johannes, Johnson, Melissa L, Mazieres, Julien, Dingemans, Anne-Marie C, Mountzios, Giannis, Pless, Miklos, Wolf, Jürgen, Schuler, Martin, Lena, Hervé, Skoulidis, Ferdinandos, Yoneshima, Yasuto, Kim, Sang-We, Linardou, Helena, Novello, Silvia, van der Wekken, Anthonie J, Chen, Yuanbin, Peters, Solange, Felip, Enriqueta, Solomon, Benjamin J, Ramalingam, Suresh S., Dooms, Christophe, Lindsay, Colin R, Ferreira, Carlos Gil, Blais, Normand, Obiozor, Cynthia C, Wang, Yang, Mehta, Bhakti, Varrieur, Tracy, Ngarmchamnanrith, Gataree, Stollenwerk, Björn, Waterhouse, David, Paz-Ares, Luis

Volltext

The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer von Steuer, Conor E., Khuri, Fadlo R., Ramalingam, Suresh S.

Volltext

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients von Kamphorst, Alice O., Pillai, Rathi N., Yang, Shu, Nasti, Tahseen H., Akondy, Rama S., Wieland, Andreas, Sica, Gabriel L., Yu, Ke, Koenig, Lydia, Patel, Nikita T., Behera, Madhusmita, Wu, Hong, McCausland, Megan, Chen, Zhengjia, Zhang, Chao, Khuri, Fadlo R., Owonikoko, Taofeek K., Ahmed, Rafi, Ramalingam, Suresh S.

Volltext

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227 von Brahmer, Julie R, Lee, Jong-Seok, Ciuleanu, Tudor-Eliade, Bernabe Caro, Reyes, Nishio, Makoto, Urban, Laszlo, Audigier-Valette, Clarisse, Lupinacci, Lorena, Sangha, Randeep, Pluzanski, Adam, Burgers, Jacobus, Mahave, Mauricio, Ahmed, Samreen, Schoenfeld, Adam J, Paz-Ares, Luis G, Reck, Martin, Borghaei, Hossein, O'Byrne, Kenneth J, Gupta, Ravi G, Bushong, Judith, Li, Li, Blum, Steven I, Eccles, Laura J, Ramalingam, Suresh S

Volltext

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC von Ramalingam, Suresh S, Vansteenkiste, Johan, Planchard, David, Cho, Byoung Chul, Gray, Jhanelle E, Ohe, Yuichiro, Zhou, Caicun, Reungwetwattana, Thanyanan, Cheng, Ying, Chewaskulyong, Busyamas, Shah, Riyaz, Cobo, Manuel, Lee, Ki Hyeong, Cheema, Parneet, Tiseo, Marcello, John, Thomas, Lin, Meng-Chih, Imamura, Fumio, Kurata, Takayasu, Todd, Alexander, Hodge, Rachel, Saggese, Matilde, Rukazenkov, Yuri, Soria, Jean-Charles

Volltext

National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer von Higgins, Kristin A., O'Connell, Kelli, Liu, Yuan, Gillespie, Theresa W., McDonald, Mark W., Pillai, Rathi N., Patel, Kirtesh R., Patel, Pretesh R., Robinson, Clifford G., Simone, Charles B., Owonikoko, Taofeek K., Belani, Chandra P., Khuri, Fadlo R., Curran, Walter J., Ramalingam, Suresh S., Behera, Madhusmita

Volltext

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 von Herbst, Roy S, Gandara, David R, Hirsch, Fred R, Redman, Mary W, LeBlanc, Michael, Mack, Philip C, Schwartz, Lawrence H, Vokes, Everett, Ramalingam, Suresh S, Bradley, Jeffrey D, Sparks, Dana, Zhou, Yang, Miwa, Crystal, Miller, Vincent A, Yelensky, Roman, Li, Yali, Allen, Jeff D, Sigal, Ellen V, Wholley, David, Sigman, Caroline C, Blumenthal, Gideon M, Malik, Shakun, Kelloff, Gary J, Abrams, Jeffrey S, Blanke, Charles D, Papadimitrakopoulou, Vassiliki A

Volltext